Diabetes drug safety update: Avandia and your heart.
出版信息
Johns Hopkins Med Lett Health After 50. 2010 Jun;22(4):1-2, 7.
PMID:20572316
Abstract
摘要
相似文献
1
Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50. 2010 Jun;22(4):1-2, 7.
2
The Avandia debate: an unhappy conclusion.
J Diabetes. 2010 Dec;2(4):221-2. doi: 10.1111/j.1753-0407.2010.00096.x.
3
Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Diabetes Care. 2007 Dec;30(12):3141-4. doi: 10.2337/dc07-1908.
4
Avandia in perspective.
US News World Rep. 2007 Oct 1;143(11):71.
5
Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett. 2007 Aug;17(12):1-2.
6
The value equation for rosiglitazone and pioglitazone in older persons.
Geriatr Nurs. 2008 Jan-Feb;29(1):9-11. doi: 10.1016/j.gerinurse.2007.11.004.
7
In brief: rosiglitazone (Avandia) unbound.
Med Lett Drugs Ther. 2014 Feb 3;56(1435):12.
8
Rosiglitazone: failure of oversight or demons imagined?
J Fam Pract. 2007 Sep;56(9):696, 703.
9
Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.
Circulation. 2010 Apr 27;121(16):1868-77. doi: 10.1161/CIR.0b013e3181d34114. Epub 2010 Feb 23.
10
Rosiglitazone, marketing, and medical science.
BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848.
引用本文的文献
1
A Small Molecule, UAB126, Reverses Diet-Induced Obesity and its Associated Metabolic Disorders.
Diabetes. 2020 Sep;69(9):2003-2016. doi: 10.2337/db19-1001. Epub 2020 Jul 1.
Zotero 插件